Immunome (NASDAQ:IMNM) Sets New 12-Month High - Here's Why
Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high, trading at $19.1150. Analysts have mixed ratings: Weiss Ratings issued a 'sell' rating, while Goldman Sachs and others have 'buy' ratings with price targets up to $26. The stock has a market cap of $1.71 billion and a P/E ratio of -6.32. Institutional investors have increased their holdings, with 44.58% of the stock owned by them. Despite a Moderate Buy consensus, some analysts suggest better investment options.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $19.05 and last traded at $19.1150, with a volume of 267180 shares. The stock had previously closed at $18.53.
Analysts Set New Price Targets
- 3 Small-Cap Stocks With Big Growth Potential
Several equities analysts have commented on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a report on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on shares of Immunome in a research note on Monday, September 22nd. They issued a "buy" rating and a $26.00 price objective on the stock. Wedbush restated an "outperform" rating and set a $21.00 price objective on shares of Immunome in a research report on Friday, November 7th. JPMorgan Chase & Co. reduced their target price on Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Finally, Guggenheim reiterated a "buy" rating and issued a $25.00 price target on shares of Immunome in a research note on Monday, August 25th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Immunome has a consensus rating of "Moderate Buy" and a consensus target price of $23.78.
Read Our Latest Research Report on IMNM
Immunome Stock Up 0.6%
The business's 50 day simple moving average is $14.41 and its two-hundred day simple moving average is $11.15. The stock has a market cap of $1.71 billion, a P/E ratio of -6.32 and a beta of 1.96.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC increased its position in Immunome by 19.1% in the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company's stock valued at $285,000 after acquiring an additional 6,792 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Immunome by 55.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company's stock worth $5,216,000 after purchasing an additional 275,000 shares during the period. Exome Asset Management LLC bought a new stake in shares of Immunome in the first quarter worth $1,776,000. Y Intercept Hong Kong Ltd acquired a new stake in Immunome in the second quarter valued at $793,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Immunome by 34.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company's stock valued at $4,135,000 after purchasing an additional 157,135 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.
Immunome Company Profile
(Get Free Report)Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Articles
- Five stocks we like better than Immunome
- Dividend Capture Strategy: What You Need to Know
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- What is Forex and How Does it Work?
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
- What Are Some of the Best Large-Cap Stocks to Buy?
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Immunome Right Now?
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
